Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 27, 2003. The report details changes in directors' interests and transactions involving the GlaxoSmithKline Employee Trust (GSK Trust).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director shareholdings.
Material Changes and Transactions
- GSK Trust Sales: On February 25, 2003, the GSK Trust sold 60,779 Ordinary Shares at £11.021 per share and 1,532 Ordinary Shares at £11.1735 per share.
- GSK Trust Transfers: The GSK Trust transferred 117,320 Ordinary Shares to participants of the Glaxo Wellcome 1999 Long Term Incentive Plan.
- Director Option Exercise: Director Mr. John D. Coombe exercised a nominal cost option (£1.00) to acquire 23,013 shares under the Glaxo Wellcome 1999 Long Term Incentive Plan.
- Director Share Sale: Mr. Coombe subsequently sold 9,225 of the acquired shares at £11.021 per share to cover tax liabilities and transaction costs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions.
Key Facts for Investor Verification
- Verify the total number of shares held by the GSK Trust following the reported sales and transfers.
- Confirm the net shareholding change for Director Mr. John D. Coombe after the option exercise and subsequent sale.
- Review the terms of the Glaxo Wellcome 1999 Long Term Incentive Plan to understand vesting conditions.
- Check the market price of GSK Ordinary Shares around February 25-27, 2003, to contextualize the transaction prices.